Medicilon won the "Best Strategic Partner" award from NewDEL Biotech in 2023

Shanghai Medicilon Inc. (Medicilon) has recently won the "Best Partner Award" from Gluetacs Therapeutics and the "2003 Best Partner Award" from SicaGene.

On January 29, Medicilon was awarded the 2023 "Best Strategic Partner" award by NewDEL Biotech.

Trust makes each other successful, Collaboration creates the future

NewDEL Biotech is the first biopharmaceutical company incubated by the Guangdong Small Molecule New Drug Innovation Center (Small Molecule Center).  Relying on the independently developed "SmartDEL technology platform" and unique living cell screening technology, a full life cycle system for innovative drugs focusing on the design, development and industrialization of FIC innovative drugs has been established to target unmet clinical needs.  In addition, dozens of R&D pipelines have been laid out.  It can be said that "innovation" has become the foundation and confidence for the development of NewDEL Biology.

Like NewDEL Biotech, Medicilon also adheres to integrity and innovation, and has successfully established a one-stop biopharmaceutical preclinical R&D service platform.  Relying on this platform, Medicilon has provided strong support for the research and development of new drugs by NewDEL Biotech.  Since the collaboration, the two parties have faced many challenges, made a lot of gratifying progress, and moved forward together.

About NewDEL Biotech

NewDEL Biotech was established in April 2021. It is an industrialized company incubated and controlled by the Guangdong Small Molecule New Drug Innovation Center.  Relying on its independently developed "SmartDEL technology platform" and unique living cell screening technology, NewDEL Biotech has established a full life cycle system for innovative drugs focusing on the design, development and industrialization of FIC innovative drugs for unmet clinical needs.  NewDEL Biotech committed to become an internationally leading and distinctive new drug R&D biopharmaceutical company.

About Medicilon

Since the founding of our company in 2004, Medicilon (Stock Code: 688202.SH) has grown into one of the professional drug discovery contract research organizations (CRO) in China.  Over the years, Medicilon keeps improving their services in biotechnology and pharmaceutical research.  Their services now span across medicinal chemistry, process chemistry, in vitro and in vivo DMPK, preclinical development and bioanalytical support.  By the end of June 2023, Medicilon has provided new drug R&D services to more than 2,000 clients around the world, and participated in the R&D of 420 new drug projects that have been approved for clinical trials.  Medicilon is proud to contribute to human health in the globe.